

## **Supplemental Figure Legends**

### **Supplemental Figure 1. Activated CD47 does not regulate other HDAC family members.**

Western immunoblot analysis of HDAC1,-2, and -4 protein expression levels in LV tissue samples from wild type (CD47<sup>+/+</sup>) (WT) and CD47 (<sup>-/-</sup>) null animals 4 weeks post-TAC or control. Densitometry is presented as the mean ( $\pm$  S.E.M.) of n = 4 animals/group.

### **Supplemental Figure 2. CD47 promotes PE-stimulated upregulation of cardiac HDAC3.**

Rat neonatal cardiac myocytes RNCM were treated with phenylephrine (PE, 10 mM)  $\pm$  a CD47 antagonist antibody (Ab) (clone OX101, 1  $\mu$ g/ml) and Western immunoblot analysis of HDAC3 protein expression performed on cell lysates. A representative blot is shown. Densitometry is presented as the mean ( $\pm$  S.E.M.) of n = 4 experiments. \* = statistically significant difference (p < 0.05) compared to untreated; # = statistically significant difference (p < 0.05) compared to PE treated.

### **Supplemental Figure 3. Oligonucleotide morpholino treatment effectively suppresses**

**HDAC3 protein expression in cardiac myocytes.** (A) RNCM were treated with a morpholino oligonucleotide to HDAC3 at the indicated concentrations or vehicle (CTRL) for 48 h, lysates prepared and protein expression determined via Western immunoblot. Densitometry is presented as the mean ( $\pm$  S.E.M.) of 4 separate experiments. \* = statistically significant difference (p < 0.05) compared to CTRL. (B) Rat neonatal cardiac myocytes were treated with BAY58-2667 (1  $\mu$ M) for 3 h, lysates prepared and protein expression of total and phosphorylated HDAC3 (p-HDAC3) determined via Western immunoblots. Densitometry is presented as the mean ( $\pm$  S.E.M.) of 3 separate experiments.

### **Supplemental Figure 4. Activated CD47 regulates CaMKII downstream targets.**

RT-PCR analysis of mRNA transcript expression levels of (A) beta myosin heavy chain ( $\beta$ -MHC), (B) atrial

natriuretic peptide (ANP), (C) alpha skeletal actin ( $\alpha$ -SKA) and (D) brain natriuretic peptide (BNP) from LV tissue samples from age matched male wild type (WT) and CD47 ( $^{-/-}$ ) null mice 4 weeks post-TAC or control. Data are presented as the mean ( $\pm$  S.E.M.). (n = 4 animals/group). Rat neonatal cardiac myocytes were treated with 7N3 (10  $\mu$ M) for 3 h, lysates prepared and RT-PCR analysis of mRNA transcript expression levels of (E)  $\beta$ -MHC and (F) BNP performed. Data are presented as the mean ( $\pm$  S.E.M.) of 3 separate experiments.


**Supplemental Figure 5. Activated CD47 regulates cardiac myocyte  $Ca^{2+}$  to control CaMKII expression.** (A) Western immunoblot analysis of phosphorylated CaMKII (p-CaMKII) and total CaMKII protein expression levels in LV samples from wild type (WT) mice  $\pm$  an HDAC3 morpholino 4 weeks post-TAC or control. Densitometry is presented as the mean ( $\pm$  S.E.M.) of n = 7 animals/group. \* = statistically significant difference (p < 0.05) compared to control; # = statistically significant difference (p < 0.05) compared to WT TAC. (B) Rat neonatal cardiac myocytes were treated with a amiloride (5 mM, 30 min) (B, C) or nifedipine (10 mM, 30 min) (D)  $\pm$  peptide 7N3 or a control (CTRL) peptide (10  $\mu$ M), lysates prepared and protein expression of CaMKII, phosphorylated CaMKII (p-CaMKII) (A, C), HDAC3 and phosphorylated HDAC3 (p-HDAC3, B) determined via Western immunoblot. Densitometry is presented as the mean ( $\pm$  S.E.M.) of 4 separate experiments. \* = statistically significant difference (p < 0.05) compared to 7N3 + amiloride and 7N3 + nifedipine.

**Supplemental Figure 6. Activated CD47, in a  $Ca^{2+}$  dependent manner, promotes autophagy marker accumulation.** (A) Rat neonatal cardiac myocytes were treated with amiloride (5 mM, 30 min, A) or nifedipine (10 mM, 30 min, B)  $\pm$  peptide 7N3, a control peptide (CTRL) (10  $\mu$ M) or vehicle (control), lysates prepared and protein expression determined via Western


immunoblot. Densitometry is presented as the mean ( $\pm$  S.E.M.) of 4 separate experiments. \* = statistically significant difference ( $p < 0.05$ ) compared to 7N3 + amiloride.



**Supplemental Figure 7. CD47 is expressed in LV biopsies from healthy subjects and dysregulated in end-stage LV HF.** (A) Western immunoblot analysis of CD47 protein expression in left ventricular tissue samples from patients with non-ischemic LV HF ( $n = 4$ ) and normal controls ( $n = 5$ ) and mRNA levels of CD47 (B) and TSP1 (C) from the same. Data are presented as the mean of all samples ( $\pm$  S.E.M.). \* = statistically significant difference ( $p < 0.05$ ) compared to control.

# Supplemental Figure 1








## Supplemental Figure 2





**A****B**




# Supplemental Figure 4











## **Supplemental Movie Legend.**

**Activation of CD47 results in a rapid increase in cytosolic calcium in cardiac myocytes.** Real-time live cell imaging of RNCM shows a rapid increase in calcium-driven fluorescence following treatment with the CD47 specific activating peptide 7N3. RNCM were cultured on glass bottom dishes, loaded with the calcium sensitive dye Fluo-4 AM (5  $\mu$ M), for 20 minutes, followed by treatment with peptide 7N3 (10  $\mu$ M). Following the addition of peptide 7N3 to the culture medium data were collected every 3 minutes over a 30 minute period employing an inverted Nikon TiE fluorescent microscope.